Interim results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy for patients with cT2-T4aN0M0 MIBC
单位：[1]Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Urol, Guangzhou, Peoples R China中山大学附属第二医院[2]Xi An Jiao Tong Univ, Dept Urol, Affiliated Hosp 1, Xian, Peoples R China[3]Huazhong Univ Sci & Technol,Tongji Hosp,Dept Urol,Tongji Med Coll,Wuhan,Peoples R China外科学系华中科技大学同济医学院附属同济医院泌尿外科[4]Anhui Med Univ, Hosp 2, Dept Urol, Hefei, Peoples R China[5]Peking Univ, Dept Urol, Peoples Hosp, Beijing, Peoples R China[6]Shandong First Med, Dept Urol, Shandong Prov Hosp, Jinan, Peoples R China
Lin Tianxin,Li Kaiwen,Fan Jinhai,et al.Interim results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy for patients with cT2-T4aN0M0 MIBC[J].JOURNAL OF CLINICAL ONCOLOGY.2022,40(16):
APA：
Lin, Tianxin,Li, Kaiwen,Fan, Jinhai,Wang, Shaogang,Yu, Dexin...&Huang, Jian.(2022).Interim results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy for patients with cT2-T4aN0M0 MIBC.JOURNAL OF CLINICAL ONCOLOGY,40,(16)
MLA：
Lin, Tianxin,et al."Interim results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy for patients with cT2-T4aN0M0 MIBC".JOURNAL OF CLINICAL ONCOLOGY 40..16(2022)
医学